Agenus has signed $141m partnership agreements with Zydus Lifesciences and its subsidiaries to enhance clinical developments ...

In this issue: assessing the regulators' role as AI in clinical trials evolves, the potential for a newborn screening refresh ...

Already offering the only non-invasive treatment for SMA in liquid form, Roche’s Evrysdi now comes as a tablet.

The European Commission (EC) has granted approval for Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin).

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma ...

SpyGlass Pharma has closed a Series D funding round, raising $75m to advance the company's drug delivery platform.

The ADC market was valued at $8.6bn in 2023, with it forecast to exceed $45bn by 2030, according to analysis by GlobalData.

The FDA set a PDUFA date in late 2025 as ziftomenib led to significant disease response in patients with common subtype of ...

The FDA has granted expanded access authorisation for ImmunityBio’s Cancer BioShield platform, anchored by Anktiva, to treat ...

Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to ...

Sanofi has signed an agreement to acquire US-based Blueprint Medicines to bolster its immunology pipeline with rare disease ...